Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
The trial will compare the overall survival of perifosine plus capecitabine to placebo plus
capecitabine in patients with refractory advanced colorectal cancer.